BML 4.80 Decreased By ▼ -0.11 (-2.24%)
BOP 12.73 Decreased By ▼ -0.33 (-2.53%)
CNERGY 7.04 Decreased By ▼ -0.08 (-1.12%)
CPHL 83.40 Decreased By ▼ -1.25 (-1.48%)
DCL 13.24 Decreased By ▼ -0.48 (-3.5%)
DGKC 171.88 Decreased By ▼ -1.46 (-0.84%)
FCCL 46.29 Decreased By ▼ -0.31 (-0.67%)
FFL 15.63 Decreased By ▼ -0.07 (-0.45%)
GCIL 26.22 Decreased By ▼ -0.45 (-1.69%)
HUBC 148.65 Decreased By ▼ -1.74 (-1.16%)
KEL 5.31 Increased By ▲ 0.04 (0.76%)
KOSM 6.25 Decreased By ▼ -0.15 (-2.34%)
LOTCHEM 20.65 Decreased By ▼ -0.11 (-0.53%)
MLCF 84.10 Decreased By ▼ -1.34 (-1.57%)
NBP 125.00 Decreased By ▼ -3.85 (-2.99%)
PAEL 40.90 Decreased By ▼ -1.15 (-2.73%)
PIAHCLA 21.88 Decreased By ▼ -0.28 (-1.26%)
PIBTL 10.13 Increased By ▲ 0.04 (0.4%)
POWER 14.00 Increased By ▲ 0.06 (0.43%)
PPL 163.48 Decreased By ▼ -0.48 (-0.29%)
PREMA 41.35 Decreased By ▼ -0.63 (-1.5%)
PRL 32.14 Decreased By ▼ -0.68 (-2.07%)
PTC 22.85 Decreased By ▼ -0.71 (-3.01%)
SNGP 115.45 Decreased By ▼ -2.52 (-2.14%)
SSGC 44.15 Decreased By ▼ -1.10 (-2.43%)
TELE 7.74 Decreased By ▼ -0.26 (-3.25%)
TPLP 9.95 Decreased By ▼ -0.17 (-1.68%)
TREET 23.40 Decreased By ▼ -0.57 (-2.38%)
TRG 55.82 Decreased By ▼ -1.19 (-2.09%)
WTL 1.50 Decreased By ▼ -0.02 (-1.32%)
BR100 14,134 Decreased By -4.9 (-0.03%)
BR30 39,571 Decreased By -563.9 (-1.4%)
KSE100 138,597 Decreased By -68.1 (-0.05%)
KSE30 42,341 Decreased By -12.3 (-0.03%)

The European Union's drug regulator is set to decide whether to approve Pfizer's COVID-19 pill at the end of this month, before doing a final review of Merck's similar but less effective drug in February, a source with knowledge of the matter said.

Late last year, the European Medicines Agency (EMA) gave guidance to member states on how to use both antiviral pills as emergency treatments, while it carried out rolling reviews to help member states decide on quick adoption ahead of any formal EU-wide approval.

Italy, Germany and Belgium are among a handful of EU countries that have bought the drugs.

The EMA's review of Merck's pill, developed with Ridgeback Biotherapeutics, is taking longer than Pfizer's because Merck released trial data in November showing its drug was significantly less effective than previously thought.

"Merck had applied earlier than Pfizer, but then they had sent the final data on efficacy later, and therefore it took European regulators more time to examine that very last data," the source said.

The source declined to be identified because the EMA's reviews are confidential.

The EMA did not immediately respond to a request for comment.

While vaccines are central to fighting the pandemic, regulators are looking at antivirals, which can be taken at home, as a new weapon against the fast-spreading Omicron variant.

US and UK regulators have given the go ahead for both drugs to treat certain high-risk adult patients.

WHO recommends reduced dose of Pfizer COVID vaccine for under 12s

The EMA said on Jan. 10 it could issue "within weeks" a decision on whether to approve the use of Pfizer's two-drug regimen Paxlovid.

In a clinical trial, it was nearly 90% effective in preventing hospitalizations and deaths when given at an early stage to patients at high risk of severe illness.

The source also said the EMA planned to issue its decision on Valneva's VLA2001 COVID-19 vaccine candidate in March, in line with the timeline given by the French company on Jan 6.

Comments

Comments are closed.